NOVN Novan Inc.

1.15
0  0%
Previous Close 1.15
Open 1.18
Price To Book -12.78
Market Cap 29965245
Shares 26,056,735
Volume 12,480
Short Ratio
Av. Daily Volume 100,880

SEC filingsSee all SEC filings

  1. 8-K - Current report 19553777
  2. 8-K - Current report 19532209
  3. 8-K - Current report 19520801
  4. 8-K - Current report 19512276
  5. CT ORDER - Confidential treatment order 181191363

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released November 29, 2016. Primary endpoint met.
SB206
Human papillomavirus (HPV)
Phase 2 data released April 12, 2017. Primary endpoint met.
SB208
Fungal infections
Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial. Additional Phase 3 trial required.
SB204
Acne vulgaris
Phase 3 trial to be initiated 1H 2019 with data due late 2019 or early 2020.
SB206
Molluscum contagiosum skin infection
Phase 1b trial completion announced August 20, 2018.
SB414
Atopic Dermatitis

Latest News

  1. Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
  2. Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now?
  3. Novan Provides Business Update
  4. Novan faces delisting from Nasdaq
  5. Cramer's Exec Cut: The biggest names in health—and Apple—...
  6. Novartis CEO on chasing cures over profitable treatments
  7. Novan shakes up leadership again
  8. Novan Announces Management Changes and Provides Business Update
  9. Stocks down in December for pharma firms in the Triangle
  10. Can We See Significant Insider Ownership On The Novan, Inc. (NASDAQ:NOVN) Share Register?
  11. Novan Announces Top-Line Data From Mid-Stage Molluscum Study
  12. Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit
  13. Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily
  14. Is WisdomTree International High Dividend Fund (DTH) a Hot ETF Right Now?
  15. Consolidated Research: 2018 Summary Expectations for Moleculin Biotech, Novan, PAVmed, Maui Land & Pineapple, Hallmark Financial Services, and McEwen Mining — Fundamental Analysis, Key Performance Indications
  16. Novan (NOVN) Reports Q3 Loss, Lags Revenue Estimates

SEC Filings

  1. 8-K - Current report 19553777
  2. 8-K - Current report 19532209
  3. 8-K - Current report 19520801
  4. 8-K - Current report 19512276
  5. CT ORDER - Confidential treatment order 181191363
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181158756
  7. 8-K - Current report 181112217
  8. 8-K - Current report 181058929
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18999894
  10. 8-K - Current report 18886812